Jinan Zhuocheng Bio-Tech Co., Ltd.

As the world's largest producer and exporter of active pharmaceutical ingredients (APIs), China has long accounted for over one-third of global production. However, for a considerable period, APIs were simplistically categorized as "advanced intermediates"—merely the final chemical synthesis step before the formulation. This perception is now being fundamentally overturned by a profound productivity transformation. Today, the manufacturing logic of APIs has shifted from "synthesizing the molecule" to "sculpting the molecule with extreme precision"—demanding accuracy, safety, traceability, scalability, and compliance with the world's most stringent multi-dimensional regulatory frameworks.

To understand this qualitative change, one must first clarify the long-blurred fundamental line between APIs and intermediates: the regulatory status transition. According to ICH Q7, from the point a substance is designated as a "starting material," it formally enters the strictly controlled scope of Good Manufacturing Practice (GMP). Thereafter, every process parameter, every piece of equipment status, and every operational record must remain under controlled conditions. In contrast, intermediate production prior to this point only requires compliance with general chemical quality systems. ICH Q11 further draws a clear red line: when the number of chemical transformation steps from the starting material to the API is too few, the regulatory review risk for starting material designation is extremely high. Regulators will never allow companies to "shrink" GMP control to just one or two simple reactions. This fundamentally negates the notion that APIs are merely an extension of intermediates.

If traditional API production was characterized by crude batch reactions driven by scale, today's API industry is being propelled from "scale-driven" to "precision-driven" by two key technologies: continuous flow chemistry and synthetic biology.

The emergence of continuous flow chemistry has transformed reactions from intermittent batch operations in reactors to continuous flow processes in microchannels or tubular reactors. This brings not only efficiency gains but also a qualitative leap in process safety and controllability. In a traditional batch reactor, a thermal runaway could scrap an entire batch or even cause a safety incident. In contrast, continuous flow systems can control residence time, mixing ratios, and temperature gradients with second-level precision, fundamentally reshaping process development methodologies. Chinese companies like Menovo have systematically improved process safety and yields by introducing continuous flow technology into the production of sartan-class APIs. Global CDMO leader Cambrex continues to expand its continuous flow platform for complex API manufacturing, such as peptides, significantly reducing solvent and reagent excess ratios and redefining the efficiency boundaries of scaled production. Even more striking is the industrial application of microfluidic technology. At the end of 2025, CHENGDU LINGTENG PHARMACEUTICAL CO., LTD., in collaboration with East China Normal University, unveiled a world-first pharmaceutical manufacturing system for ADC and nucleotide monomer synthesis. Its core breakthrough lies in using femtosecond lasers to "engrave" three-dimensional chemical factories within microchips, enabling precise chemical reactions in micro- to sub-micrometer scale channels. Traditional ADC conjugation reactions require over 12 hours at low temperatures, whereas this microfluidic system completes the process in under 20 minutes at room temperature, compressing R&D timelines by 70%. As industry experts have noted, "Synthesizing ten different drug molecules, this system running continuously for a day equals the output of ten Ph.D. students working for a week." More critically, the system supports online monitoring and closed-loop control of key quality attributes such as drug-to-antibody ratio, free toxins, and aggregates, reducing batch-to-batch variation to extremely low levels.

Another major driving force is the penetration of synthetic biology. Historically, obtaining complex molecules like chiral drugs relied heavily on efficient asymmetric synthesis, which was difficult and costly. Synthetic biology, through precise editing of microbial chassis cells, enables "cell factories" to replace traditional reactors, performing multi-step cascade catalysis. This substantially lowers production costs while expanding the boundaries of molecular complexity. The team led by Zhang Yifei at Beijing University of Chemical Technology developed a modular multi-enzyme continuous flow synthesis system. By engineering enzyme molecules with substrate tunnel engineering and combining them with continuous flow reactor design, they successfully achieved high optical purity green manufacturing of epinephrine, with a space-time yield of 2.17 grams per liter per hour. This system simultaneously overcomes common challenges in enzymatic catalysis, such as product and substrate inhibition, as well as the "scale-up effect" gap between laboratory and factory. From these technological trajectories, it is clear that API production is shifting from a "scale-up" logic to a "replication" logic: replacing geometric reactor scaling with parallel expansion of microfluidic chips, and replacing unreliable catalytic systems with engineered strains from gene editing. In this new paradigm, production capacity is no longer defined by equipment volume but by control precision and process consistency.

On the regulatory front, in January 2026, the State Council of China announced a comprehensively revised version of the "Implementing Regulations for the Drug Administration Law." This marks the first comprehensive revision in the 23 years since the regulation was implemented, with over 90% of provisions amended. This revision signifies a fundamental shift in regulatory philosophy: from a focus on managing drug production and trading enterprises to absolute lifecycle control centered on the Marketing Authorization Holder (MAH). As a result, API enterprises are being pushed to the forefront of stricter responsibility, while simultaneously capturing higher market premiums from the formulation end, significantly expanding their value-added space. Against the backdrop of accelerating global industrial chain restructuring, APIs have been endowed with geopolitical strategic significance beyond commercial interests. The United States has launched Section 232 trade investigations on pharmaceuticals, setting timelines for domestic production of critical APIs, and the FDA has increased its unannounced inspection rate for high-risk pharmaceutical companies to 25%. The European Union has implemented the Critical Medicines Act, imposing localization requirements for 276 key active substances and tilting procurement policies toward local production. API production capacity has thus become a strategic asset for measuring a nation's pharmaceutical security and supply chain resilience.

Clear signals of future industrial transformation are also evident. The explosive growth of oral small-molecule GLP-1 drugs and small nucleic acid drugs for chronic diseases will generate enormous demand for high-end APIs. However, the barriers to entering multinational pharmaceutical supply chains are extremely high. Quality system certification cycles are lengthy, requiring FDA or EMA GMP certification. From Drug Master File submission to pre-approval inspection completion often takes many months, where any minor deficiency can lead to rejection. Securing a position in the supply chains of top-tier customers has become a core competitive capability for API companies.

For veterinary drug trading companies, understanding these profound changes is crucial. The technological upgrading, stricter regulation, and geopolitical factors reshaping the API industry are fundamentally altering global supply chain dynamics. The veterinary drug sector faces similar quality requirements and regulatory pressures. Proactively adapting to the quality consistency advantages offered by continuous flow technology and synthetic biology, paying attention to the extended responsibilities of API companies under the MAH system, and capitalizing on the growing demand for high-end APIs driven by novel drugs like GLP-1s will be key variables for competitive success in future markets. Whether for human or veterinary medicine, the strategic value of APIs is no longer what it used to be. The manufacturing capabilities of precision, safety, traceability, and scalability are becoming the scarcest and most valuable core assets in the global pharmaceutical industrial chain.